New hope for melanoma patients who Don't respond to standard treatments
NCT ID NCT06999980
Summary
This trial is testing new combinations of immunotherapy drugs given before surgery for patients with advanced melanoma who are predicted to respond poorly to standard treatments. The study involves 494 patients with stage 3 skin melanoma or mucosal melanoma that can be surgically removed. Researchers want to see if these new drug combinations can better destroy cancer cells before surgery and prevent the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.